VaccineHumansCOVID-19Middle AgedMaleImmunity
Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms.
Taro Saito, Arnaud Couzinet, Toshihiro Suzuki, Manami Shimomura, Akihide Ryo, Kei Miyakawa, Yuki Katayama, Tetsuya Nakatsura
Published: 202510.1016/j.vaccine.2025.127942
Abstract
mRNA vaccines have demonstrated broad effectiveness against coronavirus disease 2019 (COVID-19); nonetheless, substantial interindividual variability in vaccine-induced immunity limits our ability to predict protective efficacy at the individual leve…
Preview only. Read the full abstract at the source